• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Trends in Lipoprotein(a) Testing at the University of Pennsylvania Health Systems from 2012-2021
Lipoprotein(a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Elevated Lp(a) levels are associated with a higher risk for myocardial infarction, coronary artery disease, aortic stenosis, and stroke. Lp(a) levels are primarily genetically driven and minimally impacted by diet and lifestyle, so a single measurement can identify individuals with elevated levels. However, Lp(a) screening has not been widely integrated into clinical practice in the United States.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Archna Bajaj, Lakshmi Parvathinathan, Marjorie Risman, Ahmad Alsattari, Daniel J. Rader Tags: Best Practices in Lipid Management Source Type: research

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease –related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform trea...
Source: Journal of Clinical Lipidology - August 28, 2022 Category: Lipidology Authors: Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, B ørge G. Nordestgaard, Carl E. Orringer Source Type: research

JCL Roundtable: Global Think Tank on Lipoprotein(a)
Lipoprotein(a) operates in causal pathways to promote atherosclerosis, arterial thrombosis, and aortic stenosis. It has been associated with rare cases of nonatherosclerotic arterial thrombotic stroke at any age. Inherited variation of lipoprotein(a) levels substantially increases cardiovascular risk in 20% of people worldwide. Recent progress in identifying the risk associated with lipoprotein(a) and in pursuing effective treatment has led to a recent Global Think Tank including representatives from the European Atherosclerosis Society, American Heart Association, Preventive Cardiovascular Nurses Association, National Lip...
Source: Journal of Clinical Lipidology - May 1, 2021 Category: Lipidology Authors: Lisa L. Maher, S. Lale Tokg özoğlu, Eduardo J. Sanchez, James A. Underberg, John R. Guyton Source Type: research

Use of lipoprotein(a) in clinical practice: A biomarker whose time has come —A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease –related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform trea...
Source: Journal of Clinical Lipidology - May 16, 2019 Category: Lipidology Authors: Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, B ørge G. Nordestgaard, Carl E. Orringer Tags: Original Research Source Type: research

Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease –related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform trea...
Source: Journal of Clinical Lipidology - May 16, 2019 Category: Lipidology Authors: Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, B ørge G. Nordestgaard, Carl E. Orringer Tags: Original Research Source Type: research

Lipoprotein(a): new insights from modern genomics
Purpose of review: Lipoprotein(a) [Lp(a)] is the strongest independent genetic risk factor for both myocardial infarction and aortic stenosis. It has also been associated with other forms of atherosclerotic cardiovascular disease (CVD) including ischemic stroke. Its levels are genetically determined and remain fairly stable throughout life. Elevated Lp(a), above 50 mg/dl, affects one in five individuals worldwide. Recent findings: Herein, we review the recent epidemiologic and genetic evidence supporting the causal role of Lp(a) in CVD, highlight recommendations made by European and Canadian guidelines regarding Lp(a) a...
Source: Current Opinion in Lipidology - March 10, 2017 Category: Lipidology Tags: GENETICS AND MOLECULAR BIOLOGY: Edited by Robert A. Hegele Source Type: research

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans Thematic Reviews
Epidemiological, genetic association, and Mendelian randomization studies have provided strong evidence that lipoprotein (a) [Lp(a)] is an independent causal risk factor for CVD, including myocardial infarction, stroke, peripheral arterial disease, and calcific aortic valve stenosis. Lp(a) levels >50 mg/dl are highly prevalent (20% of the general population) and are overrepresented in patients with CVD and aortic stenosis. These data support the notion that Lp(a) should be a target of therapy for CVD event reduction and to reduce progression of aortic stenosis. However, effective therapies to specifically reduce plasma ...
Source: The Journal of Lipid Research - March 1, 2016 Category: Lipidology Authors: Graham, M. J., Viney, N., Crooke, R. M., Tsimikas, S. Tags: Thematic Reviews Source Type: research